Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | NPY4R | P50391 | 4/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.35 |
| ▸ | NPY1R | P25929 | 3/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22267878 | 1.00 | FAP (0.37) | FAPPTGS1PTGS2NPY4RNPY5R | |
| SCHEMBL22694922 | 1.00 | FAP (0.37) | FAPPTGS1PTGS2NPY4RNPY5R | |
| SCHEMBL20935173 | 0.94 | ELANE (0.34) | FAPNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL20340684 | 0.92 | FAP (0.37) | FAPPTGS1PTGS2NPY4RNPY5R | |
| SCHEMBL19170705 | 0.91 | PTGS1 (0.34) | FAPPTGS1PTGS2ELANEFURIN | |
| SCHEMBL19681474 | 0.91 | NPY5R (0.39) | FAPPTGS1PTGS2NPY4RNPY5R | |
| SCHEMBL29308956 | 0.91 | NPY5R (0.40) | FAPPTGS1PTGS2NPY4RNPY5R | |
| SCHEMBL23436443 | 0.91 | FAP (0.34) | FAPPTGS1PTGS2NPY4RNPY5R | |
| SCHEMBL22668644 | 0.91 | FAP (0.34) | FAPPTGS1PTGS2NPY4RNPY5R | |
| SCHEMBL23420959 | 0.90 | FAP (0.37) | FAPPTGS1PTGS2NPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | GO THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-03 | — | — | US | disclosed |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2019-10-17 | — | — | US | disclosed |
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-11 | — | — | US | disclosed |
| US-10195209-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | FAP 1650/4885PTGS1 4599/4885PTGS2 4573/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | FAP 575/4885PTGS1 3958/4885PTGS2 4271/4885 |
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885PTGS1 4828/4885PTGS2 4820/4885 |
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | FAP 696/4885PTGS1 738/4885PTGS2 1278/4885 |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | CD2, CD22, CD2BP2 | FAP 1135/4885PTGS1 4486/4885PTGS2 4413/4885 |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885PTGS1 4828/4885PTGS2 4820/4885 |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885PTGS1 4828/4885PTGS2 4820/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | FAP 2388/4885PTGS1 3270/4885PTGS2 3806/4885 |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | FAP 3032/4885PTGS1 4776/4885PTGS2 4741/4885 |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | CD2, CD4, CD22 | FAP 2120/4885PTGS1 4645/4885PTGS2 4655/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | FAP 1899/4885PTGS1 4454/4885PTGS2 4662/4885 |
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | FAP 3032/4885PTGS1 4776/4885PTGS2 4741/4885 |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | MUC1, SIGLEC7, SIGLEC9 | FAP 1009/4885PTGS1 4812/4885PTGS2 4776/4885 |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | FAP 1009/4885PTGS1 4812/4885PTGS2 4776/4885 |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | FAP 4569/4885PTGS1 4828/4885PTGS2 4820/4885 |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | FAP 3032/4885PTGS1 4776/4885PTGS2 4741/4885 |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | FAP 696/4885PTGS1 738/4885PTGS2 1278/4885 |
| US-10195209-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | FAP 4569/4885PTGS1 4828/4885PTGS2 4820/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | FAP 784/4885PTGS1 788/4885PTGS2 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.